Overview - Investors & Press - T2biosystems
T2Biosystems     Print Page | Close Window

Overview

Corporate Profile

T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today. The T2Sepsis SolutionTM is a unique approach that combines the standard of care for the management of sepsis patients with T2 Biosystems’ products, including the T2Dx® Instrument and T2Candida® Panel, and the T2Bacteria® Panel, which is commercially available in Europe and other countries that accept the CE Mark and available for research use only in the U.S. Powered by the proprietary T2 Magnetic Resonance technology, or T2MR®, the T2Sepsis Solution is proven to deliver better patient care and greater cost savings. Hospital customer experience has demonstrated faster time to effective treatment, shortened ICU and hospital lengths of stay, reduced use of unnecessary antifungals, and millions of dollars in savings. T2 Biosystems has an active pipeline of future sepsis products including additional species and antibiotic resistance, as well as tests for Lyme disease and hemostasis. For more information, please visit  www.t2biosystems.com.
Stock Quote
TTOO (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$4.05
Change (%) Stock is Down 0.02 (0.49%)
Volume67,119
Data as of 10/20/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
DateTitle 
10/16/17T2 Biosystems Announces 2017 Third Quarter Financial and Operational Results Release and Conference Call Date
LEXINGTON, MA, Oct. 16, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development of innovative diagnostic products to improve patient health, today announced that it will release its 2017 third quarter financial and operational results after the market closes on Thursday, November 2, 2017. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Thursday, November 2, 2017, to disc... 
Printer Friendly Version
10/12/17Clinicians Discuss Positive Impact of T2MR Platform on Sepsis Care at IDWeek 2017
Clinicians present clinical and economic value of the T2Sepsis Solution and discuss potential of T2Bacteria Panel LEXINGTON, Mass., Oct. 12, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, today announced new data presented during the IDWeek 2017 Conference on the T2Sepsis SolutionTM, which includes the T2Bacteria® Panel, commercially available in Europe today and recently submitted ... 
Printer Friendly Version
10/03/17Study Published in Journal of Antimicrobial Stewardship Shows Patients Diagnosed with T2Candida Panel Treated More Than Eight Times Faster
T2MR platform shown to lead to appropriate therapy in 5 hours compared to 44 hours based on blood culture LEXINGTON, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, today announced that Henry Ford Health System published the clinical impact of the T2Candida Panel in The Journal of Antimicrobial Stewardship. The study, titled “T2 Magnetic Resonance Assay Improves Timel... 
Printer Friendly Version
09/21/17T2 Biosystems Announces Presentations at IDWeek 2017
LEXINGTON, MA, September 21, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, today announced a panel presentation and six poster presentations during the IDWeek 2017 Conference in San Diego, CA, held October 4-8. The panel presentation will be focused on the positive impact of the T2Candida Panel, early experiences with the T2Bacteria Research Use Only (RUO) Panel and how the deve... 
Printer Friendly Version

More News

Investor Contact Information
Contact: ir@T2Biosystems.com
(781) 761-4646

Chris Brinzey, Westwicke Partners chris.brinzey@westwicke.com
(339) 970-2843

Data provided by Nasdaq. Minimum 15 minutes delayed.